Superficial, Deep CO2 Laser Both Good for Amyloid Skin Lesions

This article originally appeared here.
Share this content:
Superficial, Deep CO<sub>2</sub> Laser Both Good for Amyloid Skin Lesions
Superficial, Deep CO2 Laser Both Good for Amyloid Skin Lesions

THURSDAY, June 25, 2015 (HealthDay News) -- For patients with primary cutaneous amyloidosis (PCA), both superficial and deep modes of fractional carbon dioxide (CO2) laser are efficacious, with the superficial mode better tolerated by patients, according to a study published in the July issue of Lasers in Surgery and Medicine.

Samia M. Esmat, M.D., from Cairo University, and colleagues assessed and compared the clinical and histological changes induced by different modes of fractional CO2 laser in PCA treatment. Data were included for 25 PCA patients (16 macular and nine lichen amyloidosis) who were treated using superficial ablation (area A) and deep rejuvenation (area B). Each patient received four treatments, with intervals of four weeks. After treatment, patients were followed for three months.

The researchers observed significant reductions in pigmentation, thickness, itching, and amyloid deposits with both modes (P < 0.001). In area A, the percentage of pigmentation reduction was significantly higher (P = 0.003). In area B, pain was significantly higher. There was a significant reduction in dermal amyloid deposits, denoting their trans-epidermal elimination, which was induced by fractional photothermolysis.

"Both superficial and deep modes of fractional CO2 laser showed comparable efficacy in treatment of PCA," the authors write. "Superficial mode, being better tolerated by patients, is recommended as a valid therapeutic option."

Abstract
Full Text (subscription or payment may be required)

Share this content:

is free, fast, and customized just for you!




Already a member?

Sign In Now »

Trending Activities

All Professions

Drug Lookup

Browse drugs by: BrandGenericDisease

More in Home

FDA Permits Marketing of Brain Stimulation Device for OCD

FDA Permits Marketing of Brain Stimulation Device for ...

FDA previously approved transcranial magnetic stimulation for major depression, certain migraines

Comments Open on End of NIH Review for Gene Therapy Studies

Comments Open on End of NIH Review for ...

NIH oversight panel no longer plans to review all applications for gene therapy experiments

U.S. Measles Outbreak Hits 107 Cases in 21 States, D.C.

U.S. Measles Outbreak Hits 107 Cases in 21 ...

Outbreak on track to exceed last year's; most of the people who got measles weren't vaccinated

is free, fast, and customized just for you!




Already a member?

Sign In Now »